DiagnoCure's Q1 Revenues Jump 90 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DiagnoCure today reported a 90 percent increase year over year in revenues for its fiscal first quarter of 2012.

For the period ended Jan. 31, revenues totaled C$556,158, (US$557,400) compared to C$292,878 a year ago. During the quarter, the Quebec City-based firm received C$268,567 from Signal Genetics for R&D services provided related to the Previstage GCC Colorectal Cancer Staging Test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.